search
Back to results

Wet Heparinized Suction for Abdominal Cancer (EUS Heparin)

Primary Purpose

Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
wet heparinzed suction
Microsieve
No heparin flush
No microsieve
Sponsored by
H. Lee Moffitt Cancer Center and Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cancer of Pancreas focused on measuring cancer, esophagus, stomach, gastric, pancreas, biliary, bile, bile duct, liver, hepatic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age ≥ 18 year
  • Non-pregnant Patients
  • Patients with the presence of a solid abdominal mass as seen on diagnostic imaging [ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA/FNB for solid pancreatic mass and did not receive a conclusive diagnosis
  • Patients with platelet count > 50,000
  • Patients with International Normalized Ratio (INR) < 1.5

Exclusion Criteria:

  • Age < 18 years
  • Pregnant Patients
  • Patients who cannot consent for themselves
  • Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days
  • Patients with cystic abdominal masses
  • Patients with a platelet count < 50,000
  • Patients with an INR > 1.5
  • Patients with a heparin or porcine allergy
  • Patients with prior heparin induced thrombocytopenia (HIT)
  • Patient's with religious aversion to porcine-containing products

Sites / Locations

  • Moffitt Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Heparin and microsieve

Heparin and no microsieve

No heparin and microsieve

No heparina nd no microsieve

Arm Description

The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue onto the microsieve

The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue into formalin

The needle not be prepped. The provider will expel the tissue onto the microsieve

The needle not be prepped. The provider will expel the tissue into formalin

Outcomes

Primary Outcome Measures

Aggregate specimen length (ASL)
sum length of all pieces of tissue obtained from EUS-FNB

Secondary Outcome Measures

Length of the longest piece (LLP)
total length of the longest tissue piece
Mean number of small pieces
defined by pieces measuring <4 mm in length
Mean number of medium pieces
defined by pieces measuring 5-8 mm in length
Means number of long pieces
defined by pieces measuring >9 mm in length
Histology adequacy score
Histology adequacy score, defined as 1, a pathologist can make a clinical diagnosis using the tissue obtained or 0 a pathologist cannot make a clinical diagnosis using the tissue obtained
Presence of a visible core specimen
defined as 1, visible tissue seen by the endoscopist at the time of tissue preparation or 0 no visible tissue seen by the endoscopist at the time of tissue preparation
Presence of visible clots in specimen
defined as 1, visible clots seen by the endoscopist at the time of tissue preparation or 0 visible clots seen by the endoscopist at the time of tissue preparation
Mean blood clot score during histology
Defined as (0: Nearly absent of red blood cells (RBC), 1+: Monolayer of RBC, no cluster formation, 2+: Aggregates of RBC present, < x40 high power field, 3+: Aggregates of RBC present, > x40 high power field).
Adequacy of diagnosis
based upon fluid washed out from the microsieve tissue sample defined by Smears with relatively abundant and well-visualized lesional material.

Full Information

First Posted
February 15, 2021
Last Updated
September 22, 2023
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05041335
Brief Title
Wet Heparinized Suction for Abdominal Cancer
Acronym
EUS Heparin
Official Title
Wet Heparinized Suction: A Novel Technique to Enhance Tissue Acquisition for Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB) of Solid Abdominal Masses: A Randomized Prospective Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 15, 2023 (Anticipated)
Primary Completion Date
December 12, 2024 (Anticipated)
Study Completion Date
December 12, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
H. Lee Moffitt Cancer Center and Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis. You will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not. You will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.
Detailed Description
Since its inception in the early 1990's, endoscopic ultrasound with fine needle aspiration (EUS-FNA) has developed into an important method for obtaining diagnostically accuracy for gastrointestinal, and extra-luminal pathology [1,2]. Present society guidelines by both the European Society of Gastrointestinal Endoscopy (ESGE) and American Society of Gastrointestinal Endoscopy (ASGE) have estimated an overall 60-90% diagnostic accuracy of EUS-FNA [2,3]. However, this accuracy is dependent upon determination of adequacy by expert gastrointestinal pathologists, which may not be available at all centers [4-6]. New developments in needle technology has led to development of "core needles", which can allow for acquisition of a tissue specimen with intact tissue architecture and therefore more ability for immunohistochemical staining (IHC). When evaluating pancreatic lesions, FNB needles have demonstrated 81-100% technical success and up to 94.7% diagnostic accuracy [18-21]. Overall, EUS-FNB appears to be a promising addition to EUS guided tissue acquisition, which has the potential of leading to improved diagnostic accuracy. As an additional means for optimizing EUS-FNB, heparin has been described and studied in the past. The study investigators have been using heparin to prime the wet suction needle to prevent formation of clot in the needle which produces "blood noodles" in the specimen that can interfere with tissue processing and interpretation. There are previous data demonstrating that heparin priming of the needle may also increase yield [22]. The study investigators have demonstrated that use of a heparin primed needle does not interfere with cytology, histology or immunohistochemical analysis, and may ease stylet handling [23]. Also, the study investigators have directly validated the use of heparin for EUS-guided liver biopsies (EUS-LB) demonstrating improvement in the size and number of histologic fragments obtained from EUS-guided biopsy [24-25]. Given this information, heparin flush is actively used and readily available, in EUS-guided biopsies here at UH. Rapid onsite cytological evaluation (ROSE) has been used to make an immediate assessment of tissue adequacy during the EUS-FNA procedure, as well as to deliver a rapid pathological diagnosis during the EUS session. ROSE has been shown to increase the yield while having the potential of decreasing the number of needle passes required. However, ROSE is not available at many EUS centers. It would be advantageous to predict adequacy of a needle biopsy specimen without having to rely on ROSE. In standard EUS-FNA practice, part of the biopsy specimens is used to prepare a smear that can be examined microscopically. The remainder of the specimen processed by the laboratory for "cell block" analysis. Microscopic examination of the smears and the cell-block are done by the pathologist to arrive at a final diagnosis. The study investigators have developed a new technique of specimen enrichment using a "microsieve device". In this technique, a small microsieve collects the larger tissue fragments, while single cells and small cell clusters wash through the microsieve. Visible tissue fragments or cores likely represent a macroscopic representation of adequacy of tissue, and could theoretically supplant ROSE in providing an on-site determination of adequacy. In the course of this study, the study investigators will collect the larger fragments as well as the wash-through and examine each separately.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver, Cancer
Keywords
cancer, esophagus, stomach, gastric, pancreas, biliary, bile, bile duct, liver, hepatic

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The control group will have 21 patients and the group receiving heparin will have 21 patients; the randomization is 1:1:1:1; heparin and microsieve, heparin and no microsieve, no heparin and microsieve and no heparin and no microsieve. Forty two subjects will be enrolled at UH for a total of 42 subjects.
Masking
ParticipantCare ProviderInvestigator
Masking Description
These needle preparations will be wrapped in non-transparent 2-inch tape to hide the appearance of the injectate agent. The needle is prepared by removing the stylet and flushing with the selected substance. The PI/Co-I will then flush the needle with the selected substance until drops of the liquid are seen exiting the needle tip. Those randomized to have the needle flushed with heparin will be termed "dry heparin" and will be flushed with 500 U heparin USP per 10 mL. Those who randomize not to receive heparin, the needle will be flushed with saline. The device shall then be placed into the linear echoendoscope and the FNB will be performed. The PI is blinded to heparin vs. no heparin only. Randomization to the microsieve vs. not is apparent to the PI.
Allocation
Randomized
Enrollment
42 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Heparin and microsieve
Arm Type
Experimental
Arm Description
The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue onto the microsieve
Arm Title
Heparin and no microsieve
Arm Type
Experimental
Arm Description
The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue into formalin
Arm Title
No heparin and microsieve
Arm Type
Experimental
Arm Description
The needle not be prepped. The provider will expel the tissue onto the microsieve
Arm Title
No heparina nd no microsieve
Arm Type
Active Comparator
Arm Description
The needle not be prepped. The provider will expel the tissue into formalin
Intervention Type
Other
Intervention Name(s)
wet heparinzed suction
Intervention Description
Needle flushed with 5000 Units in 10mL of heparin
Intervention Type
Other
Intervention Name(s)
Microsieve
Intervention Description
A microsieve used for tissue preparation
Intervention Type
Other
Intervention Name(s)
No heparin flush
Intervention Description
The needle not prepped
Intervention Type
Other
Intervention Name(s)
No microsieve
Intervention Description
The tissue is placed into formalin
Primary Outcome Measure Information:
Title
Aggregate specimen length (ASL)
Description
sum length of all pieces of tissue obtained from EUS-FNB
Time Frame
immediately after the intervention/procedure/surgery
Secondary Outcome Measure Information:
Title
Length of the longest piece (LLP)
Description
total length of the longest tissue piece
Time Frame
immediately after the intervention/procedure/surgery
Title
Mean number of small pieces
Description
defined by pieces measuring <4 mm in length
Time Frame
immediately after the intervention/procedure/surgery
Title
Mean number of medium pieces
Description
defined by pieces measuring 5-8 mm in length
Time Frame
immediately after the intervention/procedure/surgery
Title
Means number of long pieces
Description
defined by pieces measuring >9 mm in length
Time Frame
immediately after the intervention/procedure/surgery
Title
Histology adequacy score
Description
Histology adequacy score, defined as 1, a pathologist can make a clinical diagnosis using the tissue obtained or 0 a pathologist cannot make a clinical diagnosis using the tissue obtained
Time Frame
immediately after the intervention/procedure/surgery
Title
Presence of a visible core specimen
Description
defined as 1, visible tissue seen by the endoscopist at the time of tissue preparation or 0 no visible tissue seen by the endoscopist at the time of tissue preparation
Time Frame
immediately after the intervention/procedure/surgery
Title
Presence of visible clots in specimen
Description
defined as 1, visible clots seen by the endoscopist at the time of tissue preparation or 0 visible clots seen by the endoscopist at the time of tissue preparation
Time Frame
immediately after the intervention/procedure/surgery
Title
Mean blood clot score during histology
Description
Defined as (0: Nearly absent of red blood cells (RBC), 1+: Monolayer of RBC, no cluster formation, 2+: Aggregates of RBC present, < x40 high power field, 3+: Aggregates of RBC present, > x40 high power field).
Time Frame
immediately after the intervention/procedure/surgery
Title
Adequacy of diagnosis
Description
based upon fluid washed out from the microsieve tissue sample defined by Smears with relatively abundant and well-visualized lesional material.
Time Frame
immediately after the intervention/procedure/surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 year Non-pregnant Patients Patients with the presence of a solid abdominal mass as seen on diagnostic imaging [ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA/FNB for solid pancreatic mass and did not receive a conclusive diagnosis Patients with platelet count > 50,000 Patients with International Normalized Ratio (INR) < 1.5 Exclusion Criteria: Age < 18 years Pregnant Patients Patients who cannot consent for themselves Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days Patients with cystic abdominal masses Patients with a platelet count < 50,000 Patients with an INR > 1.5 Patients with a heparin or porcine allergy Patients with prior heparin induced thrombocytopenia (HIT) Patient's with religious aversion to porcine-containing products
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shaffer Mok, MD
Phone
6099804564
Email
mok.shaffer@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shaffer Mok, MD
Organizational Affiliation
Moffitt Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shaffer Mok, MD
Phone
813-745-4673
Email
Shaffer.Mok@moffitt.org

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
1568614
Citation
Vilmann P, Jacobsen GK, Henriksen FW, Hancke S. Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. Gastrointest Endosc. 1992 Mar-Apr;38(2):172-3. doi: 10.1016/s0016-5107(92)70385-x. No abstract available.
Results Reference
background
PubMed Identifier
28511234
Citation
Dumonceau JM, Deprez PH, Jenssen C, Iglesias-Garcia J, Larghi A, Vanbiervliet G, Aithal GP, Arcidiacono PG, Bastos P, Carrara S, Czako L, Fernandez-Esparrach G, Fockens P, Gines A, Havre RF, Hassan C, Vilmann P, van Hooft JE, Polkowski M. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. Endoscopy. 2017 Jul;49(7):695-714. doi: 10.1055/s-0043-109021. Epub 2017 May 16.
Results Reference
background
PubMed Identifier
23711182
Citation
Hebert-Magee S, Bae S, Varadarajulu S, Ramesh J, Frost AR, Eloubeidi MA, Eltoum IA. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology. 2013 Jun;24(3):159-71. doi: 10.1111/cyt.12071.
Results Reference
background
PubMed Identifier
21483464
Citation
Iglesias-Garcia J, Dominguez-Munoz JE, Abdulkader I, Larino-Noia J, Eugenyeva E, Lozano-Leon A, Forteza-Vila J. Influence of on-site cytopathology evaluation on the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of solid pancreatic masses. Am J Gastroenterol. 2011 Sep;106(9):1705-10. doi: 10.1038/ajg.2011.119. Epub 2011 Apr 12.
Results Reference
background
PubMed Identifier
17026562
Citation
Eloubeidi MA, Tamhane A, Jhala N, Chhieng D, Jhala D, Crowe DR, Eltoum IA. Agreement between rapid onsite and final cytologic interpretations of EUS-guided FNA specimens: implications for the endosonographer and patient management. Am J Gastroenterol. 2006 Dec;101(12):2841-7. doi: 10.1111/j.1572-0241.2006.00852.x. Epub 2006 Oct 6.
Results Reference
background
PubMed Identifier
14502798
Citation
Jhala NC, Jhala DN, Chhieng DC, Eloubeidi MA, Eltoum IA. Endoscopic ultrasound-guided fine-needle aspiration. A cytopathologist's perspective. Am J Clin Pathol. 2003 Sep;120(3):351-67. doi: 10.1309/MFRF-J0XY-JLN8-NVDP.
Results Reference
background
PubMed Identifier
15824948
Citation
Itoi T, Itokawa F, Sofuni A, Nakamura K, Tsuchida A, Yamao K, Kawai T, Moriyasu F. Puncture of solid pancreatic tumors guided by endoscopic ultrasonography: a pilot study series comparing Trucut and 19-gauge and 22-gauge aspiration needles. Endoscopy. 2005 Apr;37(4):362-6. doi: 10.1055/s-2004-826156.
Results Reference
background
PubMed Identifier
22898415
Citation
Larghi A, Capurso G, Carnuccio A, Ricci R, Alfieri S, Galasso D, Lugli F, Bianchi A, Panzuto F, De Marinis L, Falconi M, Delle Fave G, Doglietto GB, Costamagna G, Rindi G. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc. 2012 Sep;76(3):570-7. doi: 10.1016/j.gie.2012.04.477. Erratum In: Gastrointest Endosc. 2012 Nov;76(5):1085.
Results Reference
background
PubMed Identifier
22019795
Citation
Iwashita T, Yasuda I, Doi S, Ando N, Nakashima M, Adachi S, Hirose Y, Mukai T, Iwata K, Tomita E, Itoi T, Moriwaki H. Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis. Clin Gastroenterol Hepatol. 2012 Mar;10(3):316-22. doi: 10.1016/j.cgh.2011.09.032. Epub 2011 Oct 20.
Results Reference
background
PubMed Identifier
29527558
Citation
Diehl DL, Mok SRS, Khara HS, Johal AS, Kirchner HL, Lin F. Heparin priming of EUS-FNA needles does not adversely affect tissue cytology or immunohistochemical staining. Endosc Int Open. 2018 Mar;6(3):E356-E362. doi: 10.1055/s-0043-121880. Epub 2018 Mar 7.
Results Reference
background
PubMed Identifier
2981458
Citation
Kasugai H, Yamamoto R, Tatsuta M, Okano Y, Okuda S, Kishigami Y, Kitamura T, Wada A, Tamura H. Value of heparinized fine-needle aspiration biopsy in liver malignancy. AJR Am J Roentgenol. 1985 Feb;144(2):243-4. doi: 10.2214/ajr.144.2.243.
Results Reference
background
PubMed Identifier
30120956
Citation
Mok SRS, Diehl DL, Johal AS, Khara HS, Confer BD, Mudireddy PR, Kirchner HL, Chen ZE. A prospective pilot comparison of wet and dry heparinized suction for EUS-guided liver biopsy (with videos). Gastrointest Endosc. 2018 Dec;88(6):919-925. doi: 10.1016/j.gie.2018.07.036. Epub 2018 Aug 16.
Results Reference
background
PubMed Identifier
25733127
Citation
Attam R, Arain MA, Bloechl SJ, Trikudanathan G, Munigala S, Bakman Y, Singh M, Wallace T, Henderson JB, Catalano MF, Guda NM. "Wet suction technique (WEST)": a novel way to enhance the quality of EUS-FNA aspirate. Results of a prospective, single-blind, randomized, controlled trial using a 22-gauge needle for EUS-FNA of solid lesions. Gastrointest Endosc. 2015;81(6):1401-7. doi: 10.1016/j.gie.2014.11.023. Epub 2015 Feb 27.
Results Reference
background
PubMed Identifier
27530070
Citation
Schulman AR, Thompson CC, Odze R, Chan WW, Ryou M. Optimizing EUS-guided liver biopsy sampling: comprehensive assessment of needle types and tissue acquisition techniques. Gastrointest Endosc. 2017 Feb;85(2):419-426. doi: 10.1016/j.gie.2016.07.065. Epub 2016 Aug 13.
Results Reference
background
PubMed Identifier
19262518
Citation
Thomas T, Kaye PV, Ragunath K, Aithal G. Efficacy, safety, and predictive factors for a positive yield of EUS-guided Trucut biopsy: a large tertiary referral center experience. Am J Gastroenterol. 2009 Mar;104(3):584-91. doi: 10.1038/ajg.2008.97. Epub 2009 Feb 10.
Results Reference
background
PubMed Identifier
19263153
Citation
Wahnschaffe U, Ullrich R, Mayerle J, Lerch MM, Zeitz M, Faiss S. EUS-guided Trucut needle biopsies as first-line diagnostic method for patients with intestinal or extraintestinal mass lesions. Surg Endosc. 2009 Oct;23(10):2351-5. doi: 10.1007/s00464-009-0345-2. Epub 2009 Mar 5.
Results Reference
background
PubMed Identifier
26278654
Citation
Sey MS, Al-Haddad M, Imperiale TF, McGreevy K, Lin J, DeWitt JM. EUS-guided liver biopsy for parenchymal disease: a comparison of diagnostic yield between two core biopsy needles. Gastrointest Endosc. 2016 Feb;83(2):347-52. doi: 10.1016/j.gie.2015.08.012. Epub 2015 Aug 13.
Results Reference
background
PubMed Identifier
19081532
Citation
Gleeson FC, Clayton AC, Zhang L, Clain JE, Gores GJ, Rajan E, Smyrk TC, Topazian MD, Wang KK, Wiersema MJ, Levy MJ. Adequacy of endoscopic ultrasound core needle biopsy specimen of nonmalignant hepatic parenchymal disease. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1437-40. doi: 10.1016/j.cgh.2008.07.015. Epub 2008 Jul 26.
Results Reference
background
PubMed Identifier
28551024
Citation
Nieto J, Khaleel H, Challita Y, Jimenez M, Baron TH, Walters L, Hathaway K, Patel K, Lankarani A, Herman M, Holloman D, Saab S. EUS-guided fine-needle core liver biopsy sampling using a novel 19-gauge needle with modified 1-pass, 1 actuation wet suction technique. Gastrointest Endosc. 2018 Feb;87(2):469-475. doi: 10.1016/j.gie.2017.05.013. Epub 2017 May 24.
Results Reference
background
PubMed Identifier
20189503
Citation
Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available.
Results Reference
background
PubMed Identifier
21882357
Citation
Burlingame OO, Kesse KO, Silverman SG, Cibas ES. On-site adequacy evaluations performed by cytotechnologists: correlation with final interpretations of 5241 image-guided fine-needle aspiration biopsies. Cancer Cytopathol. 2012 Jun 25;120(3):177-84. doi: 10.1002/cncy.20184. Epub 2011 Aug 31.
Results Reference
background
PubMed Identifier
30648141
Citation
Mok SRS, Diehl DL, Johal AS, Khara HS, Confer BD, Mudireddy PR, Kovach AH, Diehl MM, Kirchner HL, Chen ZE. Endoscopic ultrasound-guided biopsy in chronic liver disease: a randomized comparison of 19-G FNA and 22-G FNB needles. Endosc Int Open. 2019 Jan;7(1):E62-E71. doi: 10.1055/a-0655-7462. Epub 2019 Jan 4.
Results Reference
background
PubMed Identifier
30706151
Citation
Mok SRS, Diehl DL. The Role of EUS in Liver Biopsy. Curr Gastroenterol Rep. 2019 Jan 31;21(2):6. doi: 10.1007/s11894-019-0675-8.
Results Reference
background

Learn more about this trial

Wet Heparinized Suction for Abdominal Cancer

We'll reach out to this number within 24 hrs